| abstract |
Disclosed is a dominant negative (DN) variant of transcription enhancer factor 1-related (RTEF-1). The DN RTEF-1 polypeptide may target cells directly to alter cell transcription or may be delivered in a nucleic acid expression vector. A method for inhibiting VEGF production and a method for treating angiogenic disorders such as cancer thereby are described. For example, in certain embodiments, DN RTEF-1 may be used to treat ocular angiogenic disorders such as age-related macular degeneration (AMD). [Selection figure] None |